<DOC>
	<DOCNO>NCT03004625</DOCNO>
	<brief_summary>A single-arm , multi-center study HCV-1b patient without baseline non-structure protein ( NS5A ) resistance-associated variant . Daclatasvir ( 60mg/day ) asunaprevir ( 100 mg twice daily ) plus weight-based ribavirin ( 1000-1200 mg/d ) 12 week prescribe .</brief_summary>
	<brief_title>Daclatasvir , Asunaprevir Plus Ribavirin HCV Genotype 1b Without NS5A RAV</brief_title>
	<detailed_description>Twenty-four week Daclatasvir plus Asunaprevir provide high treatment efficacy hepatitis C virus genotype 1b ( HCV-1b ) patient . Patients non-structural protein 5A ( NS5A ) resistance associate variant ( RAVs ) would inferior response . The investigator anticipate that12 week daclatasvir asunaprevir plus ribavirin highly effective HCV Genotype 1b patient without baseline NS5A RAVs .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Treatment naïve , interferonexperienced , interferonintolerant interferonineligible , HCV genotype 1b patient compensate liver disease . 2 . Patients compensate liver cirrhosis cap 40 % . Cirrhosis define one following : Liver biopsy show cirrhosis Fibroscan indicative cirrhosis evidence result &gt; 12.5 kilopascal Absence cirrhosis define one following : Liver biopsy within 2 year Screening show absence cirrhosis Fibroscan within 6 month Baseline result ≤ 12.5 kilopascal 3 . History chronic HCV infection &gt; 6 month 4 . Aged least 20 year 5 . HCV RNA 10,000 IU/mL great 6 . Negative serum urine pregnancy test result ( sensitivity 25 international unit well ) woman childbearing potential within 24hour period first dose study drug 7 . Female patient childbearing potential must agree use two reliable form effective nonhormonal contraception ( i.e. , condom , cervical barrier , intrauterine device , spermicide , sponge ) , least 1 must physical barrier method , treatment least 6 month follow last dose ribavirin . 8 . A hormonal contraception ( lieu nonhormonal ) plus physical barrier method use end treatment . All men female partner childbearing potential must use two reliable form effective contraception ( combine ) treatment 6 month follow last dose ribavirin 9 . Ability participate willingness give write informed consent comply study restriction . 1 . The existence baseline NS5A RAV `` Lycine 31 ( L31F/I/M ) '' `` Tyrosine93 ( Y93H ) '' , use directsequencing RAV &gt; 20 % . 2 . Hepatitis B virus HIV coinfection . 3 . Patients experience ascites , oesophageal varix , evidence hepatic decompensation , and/or hepatocellular carcinoma . 4 . History organ transplantation , except cornea transplantation . 5 . Hemoglobin concentration &lt; 12 g/dl male , 11 g/dl female 6 . Platelet count &lt; 50,000/mm3 7 . Prior direct antiviral agent ( DAAs ) experience . 8 . History active malignancy within last 5 year , exception localize situ carcinoma ( e.g. , basal squamous cell carcinoma skin ) 9 . History severe cardiac disease ( e.g. , New York Heart Association Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmia 's require ongoing treatment , unstable angina unstable , uncontrolled significant cardiovascular disease within 6 month ) . 10 . Poorly control diabetes ( Hemoglobin A1c value ≥ 8.5 % ) endocrine condition . 11 . Total bilirubin &gt; 2 mg/dL , unless subject documented history Gilbert 's disease . 12 . Creatinine Clearance ( CrCl ) &lt; 30 mL/min ( estimate Cockcroft Gault ) 13 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>